These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


173 related items for PubMed ID: 547652

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G, Fragiacomo C, Weidmann P, Bachmann C.
    Schweiz Med Wochenschr; 1980 Dec 06; 110(49):1875-7. PubMed ID: 7455660
    [Abstract] [Full Text] [Related]

  • 4. Clinical experience with bezafibrate.
    Schubotz R, Schneider J, Hausmann L, Mühlfellner G, Mühlfellner O, Kaffarnik H.
    Artery; 1980 Dec 06; 8(6):553-9. PubMed ID: 7259534
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Plafibride treatment of hyperlipidemias type II and IV].
    Soler J, Vinzia C, Gómez JM, Morató J.
    Med Clin (Barc); 1984 May 19; 82(19):840-2. PubMed ID: 6738212
    [No Abstract] [Full Text] [Related]

  • 7. [Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
    Kokot F, Szczechowska E.
    Z Gesamte Inn Med; 1981 Jul 01; 36(13):454-7. PubMed ID: 7025475
    [Abstract] [Full Text] [Related]

  • 8. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C, Schwartzkopff W, Schilling A, Calder D, Scheffler W.
    Artery; 1980 Jul 01; 8(2):128-33. PubMed ID: 7458677
    [Abstract] [Full Text] [Related]

  • 9. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
    Altomonte L, Mingrone G, Negrini A, De Cunto F, Greco AV.
    Clin Ter; 1981 Jan 15; 96(1):31-8. PubMed ID: 7016409
    [No Abstract] [Full Text] [Related]

  • 10. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P, Weisweiler P.
    Artery; 1980 Jan 15; 7(6):464-70. PubMed ID: 7236016
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia].
    Lageder H.
    Wien Klin Wochenschr; 1980 Feb 01; 92(3):95-101. PubMed ID: 6985560
    [Abstract] [Full Text] [Related]

  • 14. [Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
    Altomonte L, Mingrone G, Ghirlanda G, Manna R, Rebuzzi A, Pala MA, Greco AV.
    Minerva Med; 1980 Feb 11; 71(4):273-8. PubMed ID: 7354946
    [Abstract] [Full Text] [Related]

  • 15. [Clinical effects and tolerance of etofylline clofibrate].
    Ziegler WJ, Metz G, Specker M.
    Arzneimittelforschung; 1980 Feb 11; 30(11b):2053-8. PubMed ID: 7194059
    [Abstract] [Full Text] [Related]

  • 16. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M.
    Przegl Lek; 1984 Feb 11; 41(7):493-9. PubMed ID: 6390536
    [No Abstract] [Full Text] [Related]

  • 17. Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
    Kaffarnik H, Schneider J, Schubotz R, Zöfel P, Hausmann L, Goebel KM.
    Artery; 1980 Feb 11; 8(6):537-46. PubMed ID: 6114725
    [Abstract] [Full Text] [Related]

  • 18. Plafibride treatment and serum lipids in hyperlipoproteinemias.
    Rodriguez F, López IM, Jover E.
    J Med; 1987 Feb 11; 18(3-4):153-63. PubMed ID: 3323393
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Gemfibrozil--a new lipid lowering agent.
    Nash DT.
    J Med; 1980 Feb 11; 11(2-3):107-16. PubMed ID: 6931871
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.